Sphere Fluidics and PAA collaborate to offer automated micro-plate handling capabilities for single cell analysis

NewsGuard 100/100 Score

Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation (PAA), a leader in the industry for the design and manufacture of automated laboratory equipment, will collaborate to offer automated micro-plate handling capabilities for single cell analysis. PAA’s S-LAB plate handler will be integrated with Sphere Fluidics’ Cyto-Mine® Single Cell Analysis System to help increase throughput in antibody discovery and cell line development.

PAA’s S-LAB micro-plate handling capability will be integrated with the Sphere Fluidics’ Cyto-Mine® Single Cell Analysis System

Sphere Fluidics’ Cyto-Mine is an automated platform which combines single cell screening, sorting, isolation and clone verification, alleviating the need for separate instruments. Its application programming interface (API), introduced as part of the updated Cyto-Mine Studio Software Suite in 2018, enables easy communication with PAA’s innovative S-LAB automated plate handler. The integration of micro-plate handling with the Cyto-Mine will help to reduce hands-on intervention to further streamline biopharmaceutical workflows.

Dr Frank Craig, CEO, Sphere Fluidics, commented:

Our Cyto-Mine® is compatible with 96- and 384-well microtiter plates, providing a high-throughput platform for single cell analysis. By combining this with the easy-to-use automated plate handler from Peak Analysis and Automation we will be able to offer improved throughput capabilities to help reduce timelines in biotherapeutic discovery and cell-line development.”

Dr Malcolm Crook, Technical Director, Peak Analysis and Automation, said:

Our small, affordable plate handler with the reliability of a robotic arm will offer users of Sphere Fluidics’ award-winning Cyto-Mine® system a simple and flexible solution to further improve workflows and reduce costs associated with a more labor-intensive approach.”

Cyto-Mine® will be on display in Washington, DC at SLAS 2019 from 2nd to 6th February 2019 (Booth #1655 and #1429).

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New influenza vaccine strategies aim to enhance protection with T-cell responses